NCT06137469已完成1 期
A Single-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Multiple Subcutaneous Injections of SHR20004 in Healthy Subjects on Gastric Emptying
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min)
研究概览
简要总结
The purpose of this study is to investigate the impact of SHR20004 on the pharmacokinetic (PK) characteristics of acetaminophen in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntarily sign an informed consent form before participating in activities related to this trial and be able to understand the procedures and methods of the trial. Be willing to strictly follow the clinical trial protocol to complete the trial.
- •Healthy males or females aged 18-55 years (inclusive, as of signing the informed consent form).
- •Body mass index (BMI) between 19 and 28 kg/m2 (inclusive), with a weight ≥ 50 kg.
- •Have not used GLP-1 or its analogs, DPP Ⅳ inhibitors or its analogs, or other glucose-lowering drugs.
排除标准
- •Subjects with any of the following conditions or medical history:
- •Any clinical disease that the investigator determines may affect the safety or results of the study.
- •Diagnosed with diabetes according to the WHO guidelines for the diagnosis and management of diabetes.
- •A history of thyroid cancer or family history of thyroid cancer, a history of pancreatitis, or symptomatic gallstones.
- •History of severe systemic infection within 1 month of screening.
- •History of severe cardiovascular disease, including decompensated heart failure (NYHA class III or IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistent and clinically significant arrhythmia, or history of coronary artery bypass surgery or percutaneous coronary intervention.
- •Subjects with clinically significant abnormal thyroid function at screening.
- •Prolonged QTcF interval on screening or baseline ECG (male > 450 ms, female > 470 ms), or other clinically significant abnormalities that may result in a significant safety risk for the subjects.
- •Subjects with severe mental disorders.
- •Use of prescription drugs (topical eye/ nasal drops and ointments are allowed) and over-the-counter drugs, food supplements, vitamins, and Chinese herbs within 2 weeks before the start of treatment (routine vitamins are allowed).
- •Any of the following:
- •A history of recurrent or severe drug-food allergies, or known or suspected allergy to any component of the investigational drug.
- •Participation in any drug clinical trial within the past 3 months (defined as receiving trial drug treatment).
- •Consumption of more than 14 standard units of alcohol per week (1 standard unit contains 14 g of alcohol, such as 360 mL of beer or 45 mL of alcohol with a 40% alcohol content or 150 mL of wine) within the past 1 year, or a positive breath alcohol test.
- •A history of smoking (≥5 cigarettes per day for the past 1 year) or a history of smoking in the past 1 year; subjects who cannot or are unwilling to abstain from smoking during the study period, or subjects who cannot use nicotine gum or transdermal nicotine patches.
- •Long-term or consumption within the past 48 hours of coffee, tea, chocolate, or soft drinks that contain methylxanthines (theophylline, caffeine, or theobromine), such as Coca-Cola.
- •Participation in intense exercise within the past 48 hours, such as weightlifting, sprinting, long-distance running, cycling, swimming, or soccer.
- •Known or suspected history of drug abuse or a positive urine drug screening test during screening.
- •Blood donation of ≥400 mL within the past 3 months or subjects with a bleeding event of ≥400 mL within the past 3 months, such as major surgery or trauma.
- •Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C (HCV), syphilis, or human immunodeficiency virus (HIV) antibodies.
- •Subjects who are assessed by the investigator as having poor compliance or arm vein condition that cannot allow blood to be drawn, or subjects with a history of fainting or dizziness with needles.
- •Pregnant and lactating women, or male and female subjects who are of childbearing age and do not wish to use effective contraception for 2 weeks after the last dose of study medication.
- •Subjects who, in the opinion of the investigator, have any other condition that could interfere with the evaluation of the trial results.
研究组 & 干预措施
Acetaminophen+SHR20004
Experimental
干预措施: Acetaminophen/SHR20004 (Drug)
Acetaminophen+Placebo
Experimental
干预措施: Acetaminophen/Placebo (Drug)
结局指标
主要结局
Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min)
时间窗: Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31
次要结局
- Incidence and severity of AE/SAE/AESI.(Screening period up to Day 50)
- Double-delta QTcF (ΔΔQTcF)(Day 1 and Day 10 and Day 30 and Day 36)
- Concentration-delta QTcF Correlation(Day 1 and Day 10 and Day 30 and Day 36)
- Concentration-double-delta QTcF Correlation(Day 1 and Day 10 and Day 30 and Day 36)
- Immunogenicity indicators: anti-Noiiglutide antibodies(Start of treatment up to Day 50)
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (Cmax)(Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31)
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (Tmax)(Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31)
- Electrocardiographic parameters Fridericia-corrected QT interval (QTcF)(Day 1 and Day 10 and Day 30 and Day 36)
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (AUC0-60min)(Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31)
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (AUC0-60min/AUC0-300min)(Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31)
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (t1/2)(Based on pre-dose to min post-dose sampling times on Day 1 and Day 31)
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (CL/F)(Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31)
- Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (Vz/F)(Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31)
- Delta QTcF(Day 1 and Day 10 and Day 30 and Day 36)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Study of SHR0410 in Hemodialysis Patients With PruritusPruritusNCT04317209Jiangsu HengRui Medicine Co., Ltd.54
已完成
1 期
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy SubjectsThrombosisNCT04945616Jiangsu HengRui Medicine Co., Ltd.52
已完成
1 期
A Trial of SHR0410 Injection in Hemodialysis Participants.PruritusNCT03857568Atridia Pty Ltd.8
终止
1 期
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPCCastration-resistant Prostate CancerProstate CancerNCT03741712Jiangsu HengRui Medicine Co., Ltd.9
终止
2 期
A Trial of SHR0410 Injection in Postsurgical Pain ManagementPostsurgical PainNCT05394402Jiangsu HengRui Medicine Co., Ltd.31